Industry
Biotechnology
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Loading...
Open
2.98
Mkt cap
195M
Volume
804K
High
3.10
P/E Ratio
-1.95
52-wk high
7.79
Low
2.82
Div yield
N/A
52-wk low
2.38
Portfolio Pulse from
November 13, 2024 | 4:00 pm
Portfolio Pulse from
November 11, 2024 | 1:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 25, 2024 | 11:00 am
Portfolio Pulse from Benzinga Newsdesk
October 25, 2024 | 10:51 am
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 5:19 pm
Portfolio Pulse from Benzinga Newsdesk
October 17, 2024 | 12:43 pm
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 12:18 pm
Portfolio Pulse from Benzinga Newsdesk
September 26, 2024 | 12:17 pm
Portfolio Pulse from Vandana Singh
September 12, 2024 | 6:36 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.